Evolving Trends in MAb Production Processes

Overview

Journal Bioeng Transl Med

Date 2018 Jan 10

PMID 29313024

Citations 56

Authors

Abhinav A Shukla

Leslie S Wolfe

Sigma S Mostafa

Carnley Norman

Affiliations

Soon will be listed here.

Abstract

Monoclonal antibodies (mAbs) have established themselves as the leading biopharmaceutical therapeutic modality. The establishment of robust manufacturing platforms are key for antibody drug discovery efforts to seamlessly translate into clinical and commercial successes. Several drivers are influencing the design of mAb manufacturing processes. The advent of biosimilars is driving a desire to achieve lower cost of goods and globalize biologics manufacturing. High titers are now routinely achieved for mAbs in mammalian cell culture. These drivers have resulted in significant evolution in process platform approaches. Additionally, several new trends in bioprocessing have arisen in keeping with these needs. These include the consideration of alternative expression systems, continuous biomanufacturing and non-chromatographic separation formats. This paper discusses these drivers in the context of the kinds of changes they are driving in mAb production processes.

Citing Articles

Evaluating the impact of media and feed combinations on CHO cell culture performance and monoclonal antibody (trastuzumab) production.

Gyorgypal A, Chaturvedi A, Chopda V, Zhang H, Chundawat S Cytotechnology. 2025; 77(1):40.

PMID: 39803414 PMC: 11718031. DOI: 10.1007/s10616-024-00690-7.

Optimum blue light exposure: a means to increase cell-specific productivity in Chinese hamster ovary cells.

Foller S, Regett N, Lataster L, Radziwill G, Takors R Appl Microbiol Biotechnol. 2024; 108(1):530.

PMID: 39636393 PMC: 11621146. DOI: 10.1007/s00253-024-13363-4.

Assessing the Manufacturability and Critical Quality Attribute Profiles of Anti-IL-8 Immunoglobulin G Mutant Variants.

Armstrong G, Burley G, Lewis W, Rattray Z Mol Pharm. 2024; 21(12):6423-6432.

PMID: 39509699 PMC: 11615950. DOI: 10.1021/acs.molpharmaceut.4c01010.

Improving Downstream Process Related Manufacturability Based on Protein Engineering-A Feasibility Study.

Capito F, Wong T, Faust C, Brand K, Dittrich W, Sommerfeld M Eng Life Sci. 2024; 24(9):e202400019.

PMID: 39233725 PMC: 11369322. DOI: 10.1002/elsc.202400019.

Addition of sodium malonate alters the morphology and increases the critical flux during tangential flow filtration of precipitated immunoglobulins.

Behboudi A, Minervini M, Badinger Z, Haddad W, Zydney A Protein Sci. 2024; 33(6):e5010.

PMID: 38723172 PMC: 11081521. DOI: 10.1002/pro.5010.

References

Liu Z, Mostafa S, Shukla A . A comparison of protein A chromatographic stationary phases: performance characteristics for monoclonal antibody purification. Biotechnol Appl Biochem. 2014; 62(1):37-47. DOI: 10.1002/bab.1243. View

Sack M, Rademacher T, Spiegel H, Boes A, Hellwig S, Drossard J . From gene to harvest: insights into upstream process development for the GMP production of a monoclonal antibody in transgenic tobacco plants. Plant Biotechnol J. 2015; 13(8):1094-105. DOI: 10.1111/pbi.12438. View

Roopenian D, Akilesh S . FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7(9):715-25. DOI: 10.1038/nri2155. View

Gronemeyer P, Ditz R, Strube J . Trends in Upstream and Downstream Process Development for Antibody Manufacturing. Bioengineering (Basel). 2017; 1(4):188-212. DOI: 10.3390/bioengineering1040188. View

Schlehuber S, Skerra A . Anticalins as an alternative to antibody technology. Expert Opin Biol Ther. 2005; 5(11):1453-62. DOI: 10.1517/14712598.5.11.1453. View

Croughan M, Konstantinov K, Cooney C . The future of industrial bioprocessing: batch or continuous?. Biotechnol Bioeng. 2015; 112(4):648-51. DOI: 10.1002/bit.25529. View

Platis D, Labrou N . Application of a PEG/salt aqueous two-phase partition system for the recovery of monoclonal antibodies from unclarified transgenic tobacco extract. Biotechnol J. 2009; 4(9):1320-7. DOI: 10.1002/biot.200800359. View

Godawat R, Brower K, Jain S, Konstantinov K, Riske F, Warikoo V . Periodic counter-current chromatography -- design and operational considerations for integrated and continuous purification of proteins. Biotechnol J. 2012; 7(12):1496-508. DOI: 10.1002/biot.201200068. View

Ecker D, Jones S, Levine H . The therapeutic monoclonal antibody market. MAbs. 2014; 7(1):9-14. PMC: 4622599. DOI: 10.4161/19420862.2015.989042. View

10.

Potvin G, Zhang Z . Strategies for high-level recombinant protein expression in transgenic microalgae: a review. Biotechnol Adv. 2010; 28(6):910-8. DOI: 10.1016/j.biotechadv.2010.08.006. View

11.

Kusnadi A, Nikolov Z, Howard J . Production of recombinant proteins in transgenic plants: Practical considerations. Biotechnol Bioeng. 2008; 56(5):473-84. DOI: 10.1002/(SICI)1097-0290(19971205)56:5<473::AID-BIT1>3.0.CO;2-F. View

12.

Shukla A, Hinckley P . Host cell protein clearance during protein A chromatography: development of an improved column wash step. Biotechnol Prog. 2009; 24(5):1115-21. DOI: 10.1002/btpr.50. View

13.

McDonald P, Victa C, Carter-Franklin J, Fahrner R . Selective antibody precipitation using polyelectrolytes: a novel approach to the purification of monoclonal antibodies. Biotechnol Bioeng. 2008; 102(4):1141-51. DOI: 10.1002/bit.22127. View

14.

Birch J, Racher A . Antibody production. Adv Drug Deliv Rev. 2006; 58(5-6):671-85. DOI: 10.1016/j.addr.2005.12.006. View

15.

Gottschalk U . Bioseparation in antibody manufacturing: the good, the bad and the ugly. Biotechnol Prog. 2008; 24(3):496-503. DOI: 10.1021/bp070452g. View

16.

Shukla A, Jiang C, Ma J, Rubacha M, Flansburg L, Lee S . Demonstration of robust host cell protein clearance in biopharmaceutical downstream processes. Biotechnol Prog. 2008; 24(3):615-22. DOI: 10.1021/bp070396j. View

17.

Shukla A, Gottschalk U . Single-use disposable technologies for biopharmaceutical manufacturing. Trends Biotechnol. 2012; 31(3):147-54. DOI: 10.1016/j.tibtech.2012.10.004. View

18.

Rosenberg Y, Sack M, Montefiori D, Forthal D, Mao L, Hernandez-Abanto S . Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. PLoS One. 2013; 8(3):e58724. PMC: 3606348. DOI: 10.1371/journal.pone.0058724. View

19.

Lee Y, Jeong K . Challenges to production of antibodies in bacteria and yeast. J Biosci Bioeng. 2015; 120(5):483-90. DOI: 10.1016/j.jbiosc.2015.03.009. View

20.

Shukla A, Hubbard B, Tressel T, Guhan S, Low D . Downstream processing of monoclonal antibodies--application of platform approaches. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 848(1):28-39. DOI: 10.1016/j.jchromb.2006.09.026. View